ArticlePLoS neglected tropical diseases2026
An automated end-to-end system for schistosome viability assessment to accelerate anti-schistosomal drug discovery.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schistosomiasis, a neglected tropical disease affecting millions globally, urgently requires new therapies. Current treatments, like praziquantel (PZQ), face challenges such as drug resistance and ineffectiveness against juvenile parasites. This study develops an automated, high-throughput computational platform to quantify schistosome viability from video data. We introduced an end-to-end system that leverages foundation models in computer vision and fine-tuning to assess schistosome viability from videos. By fine-tuning advanced image segmentation and spatiotemporal feature representation models, our approach accurately captures both morphological and motility-related features of schistosome and maps them to worm viability directly. As a proof of concept, we constructed two datasets (a PZQ-treatment video dataset with 325 videos and a multi-compound treatment video dataset with 245 videos), designed three worm viability assessment tasks and performed extensive evaluation on them. In addition, we developed a schistosome viability scoring tool, which can be accessed online. The system achieved superior predictive accuracy in PZQ-treated worms, with a Pearson correlation coefficient (PCC) of 0.937 for concentration regression, outperforming approaches like hand-crafted feature methods and wrmXpress. A novel 24-hour equivalent PZQ concentration metric was introduced, addressing saturation effects and showing strong generalizability across 13 other compounds (PCC = 0.712). Direct viability score predictions correlated highly with expert assessments, with PCCs of 0.892 for multi-worm analyses and 0.831 for individual worms. We developed a scalable, automated platform for anti-schistosomal drug discovery, providing reliable viability assessments. An accessible online tool enables efficient screening and has broader implications for parasitological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.